Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).
Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ENGOT-OV16/NOVA study on the long-term safety and efficacy of niraparib as maintenance therapy in patients with platinum-sensitive ovarian cancer with either a BRCA mutation or a tumor with high-grade serous histology. Women in the study have responded to their most recent chemotherapy containing a platinum agent (ID #: 11139).
Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict the efficacy of olaparib plus bevacizumab in first-line maintenance therapy for patients with ovarian cancer (ID# 10224).
Dana M. Roque, MD, of the University of Maryland Medical Center, discusses phase II results showing that weekly ixabepilone plus biweekly bevacizumab may improve overall response rate as well as progression-free and overall survival for women with platinum-resistant or -refractory ovarian, fallopian tube, and primary peritoneal cancers, a population in need of treatment choices.
